drug
diazoxide choline ER
Marketedupdated 6mo agoby $SLNO SOLENO THERAPEUTICS INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying diazoxide choline ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 20, 2026
33 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Nov 12, 2035method-of-use (U-4167)US 12178823
- Nov 12, 2035method-of-use (U-4167)US 12178823
- Nov 12, 2035method-of-use (U-4167)US 12178823
- Nov 12, 2035method-of-use (U-4211)US 12343348
- Nov 12, 2035method-of-use (U-4211)US 12343348
- Nov 12, 2035method-of-use (U-4211)US 12343348
- Nov 12, 2035method-of-use (U-4275)US 12419895
- Nov 12, 2035method-of-use (U-4275)US 12419895
- Nov 12, 2035method-of-use (U-4275)US 12419895
- Nov 12, 2035method-of-use (U-4167)US 9757384
- Nov 12, 2035method-of-use (U-4167)US 9757384
- Nov 12, 2035method-of-use (U-4167)US 9757384
- Mar 5, 2029compositionUS 77997772.3y
- Mar 5, 2029compositionUS 77997772.3y
- Mar 5, 2029compositionUS 77997772.3y
- Dec 20, 2026compositionUS 757278933d
- Dec 20, 2026compositionUS 757278933d
- Dec 20, 2026compositionUS 757278933d
FDA exclusivities (3)
- Mar 26, 2028NPNP1.4y
- Mar 26, 2028NPNP1.4y
- Mar 26, 2028NPNP1.4y
News(10)
- Neurocrine defends Prader-Willi drug after another patient deathNeurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.biospace · 13d ago
- FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concernsAfter cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aa…biospace · 24d ago
- STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and morePatient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drugstat · 1mo ago
- STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drugPatient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.stat · 1mo ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 2mo ago
- Four questions on new safety warnings for Neurocrine’s Vykat XRA group of experts on Prader-Willi syndrome has sounded the alarm on side effects and deaths that may be connected to Neurocrine Biosciences’ medicine Vykat XR. The treatment has been linked to sev…endpoints · 3mo ago
- Deaths reported after treatment with Neurocrine’s approved Prader-Willi drugReports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day f…biospace · 3mo ago
- STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and moreEli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutidestat · 3mo ago
- STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts sayA newly approved drug for Prader-Willi syndrome, a rare disease that causes an insatiable desire to eat, may be tied to a series of patient deaths, experts say.stat · 3mo ago
- Novo’s late-stage IL-6 stumble shakes inflammation spaceNovo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s…biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that